Overview
Dr. Kathleen Welsh-Bohmer is a Professor of Psychiatry with a secondary appointment in the Department of Neurology.
Clinically trained as a neuropsychologist, Dr. Welsh-Bohmer's research activities have been focused around developing effective prevention and treatment strategies to delay the onset of cognitive disorders occurring in later life. From 2006 through 2018 she directed the Joseph and Kathleen Bryan Alzheimer’s Center in the Department of Neurology. She also oversaw the neuropsychology scientific operations of a ground-breaking Phase III global clinical trial to delay the onset of early clinical symptoms of Alzheimer’s disease entitled the “TOMMORROW” study (Takeda Pharmaceutical Company funded) which concluded in 2018.
Currently, she directs the Alzheimer's disease therapeutic area within the Duke Clinical Research Institute and she collaborates actively with VeraSci, a Durham based company, to develop reliable digital cognitive and functional assessment tools of early Alzheimer's disease and related dementias. The methods her team is developing are informed by advances in neuroscience and technology and fill an information void in early pre-clinical Alzheimer's disease. Her work has implications for clinical practice and for the acceleration of global clinical trials aimed at the prevention of Alzheimer’s disease and related dementias.
Clinically trained as a neuropsychologist, Dr. Welsh-Bohmer's research activities have been focused around developing effective prevention and treatment strategies to delay the onset of cognitive disorders occurring in later life. From 2006 through 2018 she directed the Joseph and Kathleen Bryan Alzheimer’s Center in the Department of Neurology. She also oversaw the neuropsychology scientific operations of a ground-breaking Phase III global clinical trial to delay the onset of early clinical symptoms of Alzheimer’s disease entitled the “TOMMORROW” study (Takeda Pharmaceutical Company funded) which concluded in 2018.
Currently, she directs the Alzheimer's disease therapeutic area within the Duke Clinical Research Institute and she collaborates actively with VeraSci, a Durham based company, to develop reliable digital cognitive and functional assessment tools of early Alzheimer's disease and related dementias. The methods her team is developing are informed by advances in neuroscience and technology and fill an information void in early pre-clinical Alzheimer's disease. Her work has implications for clinical practice and for the acceleration of global clinical trials aimed at the prevention of Alzheimer’s disease and related dementias.
Current Appointments & Affiliations
Professor in Psychiatry and Behavioral Sciences
·
2021 - Present
Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences,
Psychiatry & Behavioral Sciences
Director of Outreach and Recruitment Core of Duke/UNC Alzheimer Disease Research Center
·
2021 - Present
Center for the Study of Aging and Human Development,
Institutes and Centers
Professor of Psychology and Neuroscience
·
2013 - Present
Psychology & Neuroscience,
Trinity College of Arts & Sciences
Professor in Neurology
·
2015 - Present
Neurology, Behavioral Neurology,
Neurology
Faculty Network Member of the Duke Institute for Brain Sciences
·
2014 - Present
Duke Institute for Brain Sciences,
University Institutes and Centers
Member in the Duke Clinical Research Institute
·
2018 - Present
Duke Clinical Research Institute,
Institutes and Centers
Education, Training & Certifications
University of Virginia ·
1985
Ph.D.